Expert Review of Pharmacoeconomics & Outcomes Research

Papers
(The H4-Index of Expert Review of Pharmacoeconomics & Outcomes Research is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
A landscape analysis and discussion of value of gene therapies for sickle cell disease48
Adherence to augmentation therapy for the treatment of major depressive disorder38
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment26
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy23
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation20
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran20
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening18
The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature17
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain16
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review15
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care15
The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study14
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients13
Social care data in the UK; current landscape, challenges, and future recommendations13
0.11673212051392